Diaceutics PLC Block Listing Application to AIM (4207O)

TIDMDXRX

RNS Number : 4207O

Diaceutics PLC

02 October 2023

Block Listing Application to AIM

Belfast and London, 2 October 2023 - Diaceutics PLC (AIM: DXRX) , a leading technology and solutions provider to the pharmaceutical industry, today announces an application has been made to AIM for a block listing of 1,500,000 ordinary shares of GBP0.002 each in the Company ("Ordinary Shares"). This will be used to facilitate the admission of shares to trading following the exercise of options granted under the following Company's share schemes:

 
      --   the UK and Global Share Incentive Plan for employees 
            (the "SIP"); and 
      --   the Employee Share Option Plan (the "ESOP") which includes 
            long term incentive awards.

The Ordinary Shares will be issued from time to time pursuant to the Company's existing plans including outstanding options already issued but not yet exercised to the employees of the Company. New Ordinary Shares issued following option exercises and admitted to trading under the block admission will rank pari passu in all respects with the existing Ordinary Shares.

The block listing is expected to become effective on or around 6 October 2023. The Company will make six-monthly announcements of the utilisation of the block admission, in line with its obligation under AIM Rule 29.

At the time of this announcement, Diaceutics has 84,472,431 Ordinary Shares in issue. This figure may be used by shareholders in the Company as a denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information from Diaceutics PLC, please contact:

Enquiries:

 
Diaceutics PLC                         Tel: +44 (0)28 9040 6500 
Nick Roberts, Chief Financial Officer  investorrelations@diaceutics.com 
 
Stifel Nicolaus Europe Limited (Nomad  Tel: +44 (0)20 7710 7600 
 & Broker) 
Ben Maddison 
Nick Harland 
Kate Hanshaw 
 
Alma                                   Tel: +44(0)20 3405 0205 
Caroline Forde                         diaceutics@almapr.co.uk 
Matthew Young 
Kinvara Verdon

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network (R)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCBSBDGDUGDGXD

(END) Dow Jones Newswires

October 02, 2023 10:59 ET (14:59 GMT)

Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2024 to May 2024